Transformative arrival of oral weight loss medicines in the US [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
option than injectable Wegovy or Eli Lilly's (US) once-weekly injectable GLP-1 medicine Zepbound. While GlobalData does not expect oral Wegovy to substantially displace sales of injectable versions in 2026, some sales cannibalisation in the medium-term outlook is inevitable. Nevertheless, new market opportunities are also present for individuals who find injections off-putting. The ease-of-use appeal may also increase the number of patients willing to try weight loss treatment in the first place and mean that more patients adhere to prescriptions for longer. In addition, oral Wegovy could reach an untapped market of individuals who want to use the drug in a more ad hoc fashion to maintain target weights or for short periods during key life events (such as holidays and weddings). Judging the size of the expansive oral weight loss market is difficult. In the past, Novo Nordisk has been caught out by sudden spikes and dips in consumer demand for injectable Wegovy, and similar surpris
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE:LLY) had its price target lowered by analysts at Guggenheim from $1,163.00 to $1,161.00. They now have a "buy" rating on the stock.MarketBeat
- Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancerPR Newswire
- Smaller portions, more protein: How GLP-1s are quietly changing chain restaurant menus [MSNBC.com]MSNBC.com
- Prediction: 2026 Will Be the Year of Eli Lilly [Yahoo! Finance]Yahoo! Finance
- What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- LLY's page on the SEC website